Form 4: Coherus BioSciences CEO Dennis Lanfear Reports Stock Transaction

Coherus BioSciences CEO Dennis Lanfear had 11,810 shares withheld to cover tax liabilities related to vesting restricted stock units.

Summary

• Dennis Lanfear, CEO of Coherus BioSciences, reported a transaction involving the withholding of 11,810 common stock shares to cover tax obligations.
• The transaction occurred on January 20, 2025, with the shares withheld at a price of $1.39 per share.
• Following the transaction, Lanfear directly owns 685,074 shares of Coherus BioSciences stock.
• He also indirectly owns 432,684 shares through the Lanfear Revocable Trust and 86,965 shares through Lanfear Capital Advisors, LLC.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is a common occurrence related to the vesting of restricted stock units and the subsequent tax obligations.
• Similar filings are made by executives at companies like Amgen, Gilead, and Regeneron when they have similar stock transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine tax withholding event.

Key Dates

Keywords

Coherus BioSciences, Dennis Lanfear, stock transaction, Form 4, insider trading, tax withholding, equity securities, beneficial ownership